Tumor-specific diagnostic marker for transmissible facial tumors of tasmanian devils: Immunohistochemistry studies

Veterinary Pathology

Volumn 48, Issue 6, 2011, Pages 1195-1203

  Tovar, C ^a   Obendorf, D ^b   Murchison, E P ^c   Papenfuss, A T ^d   Kreiss, A ^a   Woods, G M ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

devil facial tumor disease; DFTD; immunohistochemistry; periaxin; Tasmanian devil

Indexed keywords

MEMBRANE PROTEIN; PERIAXIN; TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; ARTICLE; CELL CULTURE; FACE TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; MALE; MARSUPIAL; METABOLISM; MOUSE; NERVE SHEATH TUMOR; PATHOLOGY; SCHWANN CELL; SCID MOUSE; SENSITIVITY AND SPECIFICITY; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; CELLS, CULTURED; FACIAL NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; HETEROGRAFTS; IMMUNOHISTOCHEMISTRY; MALE; MARSUPIALIA; MEMBRANE PROTEINS; MICE; MICE, SCID; NERVE SHEATH NEOPLASMS; SCHWANN CELLS; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; SARCOPHILUS HARRISII;

EID: 79960637538     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985811400447     Document Type: Article

References (42)

1. Bundza A,Dukes TW,Stead RH.Peripheral nerve sheath neoplasms in Canadian slaughter cattle.Can Vet J. 1986;27 (7): 268-271.
2. Canfield PJ,Cunningham AA.Disease and mortality in Australasian marsupials held at London Zoo, 1872-1972.J Zoo Wildl Med. 1993;24 (2): 158-167.
3. Canfield PJ,Hemsley S.The roles of histology and immunohistology in the investigation of marsupial disease and normal lymphoid tissue.Dev Comp Immunol. 2000;24 (5): 455-471.
4. Carroll SL,Ratner N.How does the Schwann cell lineage form tumors in NF1?.Glia. 2008;56 (14): 1590-1605.
5. Chijiwa K,Uchida K,Tateyama S.Immunohistochemical evaluation of canine peripheral nerve sheath tumors and other soft tissue sarcomas.Vet Pathol. 2004;41 (4): 307-318.
6. Coindre JM.Immunohistochemistry in the diagnosis of soft tissue tumours.Histopathology. 2003;43 (1): 1-16.
7. Dundr P,Povysil C,Tvrdik D.Actin expression in neural crest cell-derived tumors including schwannomas, malignant peripheral nerve sheath tumors, neurofibromas and melanocytic tumors.Pathol Int. 2009;59 (2): 86-90.
8. Dupin E,Calloni G,Real C, et al.Neural crest progenitors and stem cells.C R Biol. 2007;330 ((6-7)): 521-529.
9. Gillespie CS,Sherman DL,Blair GE, et al.Periaxin, a novel protein of myelinating Schwann cells with a possible role in axonal ensheathment.Neuron. 1994;12 (3): 497-508.
10. Griner LA.Neoplasms in Tasmanian devils (Sarcophilus harrisii).J Natl Cancer Inst. 1979;62 (3): 589-595.
11. Gupta G,Mammis A,Maniker ANeurosurg Clin N Am 19(4):533-543, v. 2008:.
12. Hamede R,McCallum H,Jones M.Seasonal, demographic and density-related patterns of contact between Tasmanian devils (Sarcophilus harrisii): implications for transmission of devil facial tumour disease.Austral Ecol. 2008;33 (5): 614-622.
13. Hawkins CE,Baars C,Hesterman H, et al.Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii.Biol Conserv. 2006;131 (2): 307-324.
14. Hendy GN,Bevan S,Mattei MG, et al.Chromogranin A.Clin Invest Med. 1995;18 (1): 47-65.
15. Hoshi N,Hiraki H,Yamaki T, et al.Frequent expression of 75 kDa nerve growth factor receptor and phosphotyrosine in human peripheral nerve tumours: an immunohistochemical study on paraffin-embedded tissues.Virchows Arch. 1994;424 (5): 563-568.
16. Jones M,Jarman P,Lees C, et al.Conservation management of Tasmanian devils in the context of an emerging, extinction-threatening disease: devil facial tumor disease.EcoHealth. 2007;4 (3): 326-337.
17. Joseph NM,Mukouyama YS,Mosher JT, et al.Neural crest stem cells undergo multilineage differentiation in developing peripheral nerves to generate endoneurial fibroblasts in addition to Schwann cells.Development. 2004;131 (22): 5599-5612.
18. Kreiss A,Fox N,Bergfeld J, et al.Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii).Dev Comp Immunol. 2008;32 (5): 544-553.
19. Kreiss A,Tovar C,Obendorf DL, et al.A murine xenograft model for a transmissible cancer in Tasmanian devils.Vet Pathol. in press;:.
20. Le Douarin NM,Calloni GW,Dupin E.The stem cells of the neural crest.Cell Cycle. 2008;7 (8): 1013-1019.
21. Loh R,Bergfeld J,Hayes D, et al.The pathology of devil facial tumor disease (DFTD) in Tasmanian devils (Sarcophilus harrisii).Vet Pathol. 2006;43 (6): 890-895.
22. Loh R,Hayes D,Mahjoor A, et al.The immunohistochemical characterization of devil facial tumor disease (DFTD) in the Tasmanian devil (Sarcophilus harrisii).Vet Pathol. 2006;43 (6): 896-903.
23. Marangos PJ,Schmechel DE.Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells.Annu Rev Neurosci. 1987;10:269-295.
24. Mauritz C,Grothe C,Haastert K.Comparative study of cell culture and purification methods to obtain highly enriched cultures of proliferating adult rat Schwann cells.J Neurosci Res. 2004;77 (3): 453-461.
25. McCallum H,Jones M.To lose both would look like carelessness: Tasmanian devil facial tumour disease.PLoS Biol. 2006;4 (10): e342.
26. McCallum H,Tompkins D,Jones M, et al.Distribution and impacts of Tasmanian devil facial tumor disease.EcoHealth. 2007;4 (3): 318-325.
27. Mikkelsen TS,Wakefield MJ,Aken B, et al.Genome of the marsupial Monodelphis domestica reveals innovation in non-coding sequences.Nature. 2007;447 (7141): 167-177.
28. Murchison EP,Tovar C,Hsu A, et al.The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer.Science. 2010;327 (5961): 84-87.
29. Natkunam Y,Mason DY.Prognostic immunohistologic markers in human tumors: Why are so few used in clinical practice?.Lab Invest. 2006;86 (8): 742-747.
30. Nielsen AB,Jansen EC,Leifsson PS, et al.Immunoreactivity of bovine schwannomas.J Comp Pathol. 2007;137 (4): 224-230.
31. Nonaka D,Chiriboga L,Rubin BP.Sox10: a pan-schwannian and melanocytic marker.Am J Surg Pathol. 2008;32 (9): 1291-1298.
32. Obendorf DL,McGlashan ND.Research priorities in the Tasmanian devil facial tumour debate.Eur J Oncol. 2008;13 (4): 229-238.
33. Pearse AM,Swift K.Allograft theory: transmission of devil facial-tumour disease.Nature. 2006;439 (7076): 549.
34. Sandberg A.AThe genetics and molecular biology of neural tumors. Sandberg A.AStone J.F, ed. Totowa, NJ: Humana Press; 2008:43-81.
35. Schmechel D,Marangos PJ,Brightman M.Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells.Nature. 1978;276 (5690): 834-836.
36. Schoniger S,Summers BA.Localized, plexiform, diffuse, and other variants of neurofibroma in 12 dogs, 2 horses, and a chicken.Vet Pathol. 2009;46 (5): 904-915.
37. Schulman FY,Johnson TO,Facemire PR, et al.Feline peripheral nerve sheath tumors: histologic, immunohistochemical, and clinicopathologic correlation (59 tumors in 53 cats).Vet Pathol. 2009;46 (6): 1166-1180.
38. Shimada S,Tsuzuki T,Kuroda M, et al.Nestin expression as a new marker in malignant peripheral nerve sheath tumors.Pathol Int. 2007;57 (2): 60-67.
39. Siddle HV,Sanderson C,Belov K.Characterization of major histocompatibility complex class I and class II genes from the Tasmanian devil (Sarcophilus harrisii).Immunogenetics. 2007;59 (9): 753-760.
40. Stasik CJ,Tawfik O.Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor).Arch Pathol Lab Med. 2006;130 (12): 1878-1881.
41. Woods GM,Kreiss A,Belov K, et al.The immune response of the Tasmanian devil (Sarcophilus harrisii) and devil facial tumor disease.EcoHealth. 2007;4 (3): 338-345.
42. Wu JM,Montgomery E.Classification and pathology.Surg Clin North Am. 2008;88 (3): 483-520.